Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H.

JAMA Oncol. 2018 Sep 1;4(9):1199-1206. doi: 10.1001/jamaoncol.2018.1380.

PMID:
29852043
3.

Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).

Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A.

Eur J Cancer. 2018 Jul;97:33-40. doi: 10.1016/j.ejca.2018.03.007. Epub 2018 Apr 21.

PMID:
29685343
4.

Primary bone lymphoma presenting as skeletal lesions in a patient recently treated for prostate cancer.

Kordes M, Yachnin J.

Acta Oncol. 2018 May;57(5):700-703. doi: 10.1080/0284186X.2017.1404636. Epub 2017 Nov 22. No abstract available.

PMID:
29164979
5.

The In Vitro Stability of Circulating Tumour DNA.

Henao Diaz E, Yachnin J, Grönberg H, Lindberg J.

PLoS One. 2016 Dec 13;11(12):e0168153. doi: 10.1371/journal.pone.0168153. eCollection 2016.

6.

Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells.

Ronquist KG, Sanchez C, Dubois L, Chioureas D, Fonseca P, Larsson A, Ullén A, Yachnin J, Ronquist G, Panaretakis T.

J Extracell Vesicles. 2016 Mar 7;5:29877. doi: 10.3402/jev.v5.29877. eCollection 2016.

7.

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.

Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T.

Oncotarget. 2015 Aug 28;6(25):21740-54.

8.

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.

Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade JL.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1241-52. doi: 10.1007/s00280-014-2460-6. Epub 2014 Apr 10.

PMID:
24718982
9.

DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.

Eriksson F, Tötterman T, Maltais AK, Pisa P, Yachnin J.

Vaccine. 2013 Aug 20;31(37):3843-8. doi: 10.1016/j.vaccine.2013.06.063. Epub 2013 Jul 2.

PMID:
23831327
10.

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Karussis D, Shor H, Yachnin J, Lanxner N, Amiel M, Baruch K, Keren-Zur Y, Haviv O, Filippi M, Petrou P, Hajag S, Vourka-Karussis U, Vaknin-Dembinsky A, Khoury S, Abramsky O, Atlan H, Cohen IR, Abulafia-Lapid R.

PLoS One. 2012;7(12):e50478. doi: 10.1371/journal.pone.0050478. Epub 2012 Dec 14.

11.

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO.

J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.

PMID:
22965953
12.

[Difficulties and bureaucracy threat against clinical research].

Yachnin J, Enblad G.

Lakartidningen. 2010 Jun 9;107(23):1525-6. Swedish. No abstract available.

PMID:
20617772
13.

Oxaliplatin neurotoxicity--no general ion channel surface-charge effect.

Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Elinder F.

J Negat Results Biomed. 2009 Jan 12;8:2. doi: 10.1186/1477-5751-8-2.

14.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS.

Lancet Oncol. 2007 Jul;8(7):587-94.

PMID:
17544845
15.

Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate.

Jerremalm E, Wallin I, Yachnin J, Ehrsson H.

Eur J Pharm Sci. 2006 Jul;28(4):278-83. Epub 2006 Apr 18.

PMID:
16621479
16.

Pharmacokinetics of oxaliplatin in humans.

Ehrsson H, Wallin I, Yachnin J.

Med Oncol. 2002;19(4):261-5.

PMID:
12512920
17.

Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin.

Videhult P, Yachnin J, Jerremalm E, Lewensohn R, Ehrsson H.

Cancer Lett. 2002 Jun 28;180(2):191-4.

PMID:
12175551
18.

DNA-dependent protein kinase is inhibited by trifluoperazine.

Eriksson A, Yachnin J, Lewensohn R, Nilsson A.

Biochem Biophys Res Commun. 2001 May 18;283(4):726-31. Erratum in: Biochem Biophys Res Commun 2001 Jun 22;284(4):1091. Nilsso A [corrected to Nilsson A].

PMID:
11350043
19.

The kinetics and cytotoxicity of cisplatin and its monohydrated complex.

Yachnin JR, Wallin I, Lewensohn R, Sirzén F, Ehrsson H.

Cancer Lett. 1998 Oct 23;132(1-2):175-80.

PMID:
10397471

Supplemental Content

Loading ...
Support Center